Dubai: The Emirates Drug Establishment (EDE) has announced the registration of Blenrep (Belantamab Mafodotin) as an ...

GSK (GSK.L) expects to deliver annual sales and profit growth towards the top end of its forecasts after beating ...

Blenrep approved in the EU for multiple myeloma | Regulatory NewsThe approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

The FTSE 100 has continued to notch fresh highs, as UK stocks have been swept in broader market optimism around developments on US tariffs.

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

Swiss banking giant UBS said Wednesday that its net profit doubled in the second quarter thanks to a surge in transactions ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...